Coexpression cluster:C1225: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{ | |||
Latest revision as of 11:40, 17 September 2013
Full id: C1225_thymus_acute_CD4_CD8_Hodgkin_Peripheral_lymph
Phase1 CAGE Peaks
Hg19::chr17:29637535..29637559,+ | p@chr17:29637535..29637559 + |
Hg19::chr2:95740679..95740695,+ | p@chr2:95740679..95740695 + |
Hg19::chr4:109089436..109089456,- | p22@LEF1 |
Hg19::chr4:109089457..109089474,- | p29@LEF1 |
Hg19::chr4:109092943..109092955,+ | p4@ENST00000508266 |
Hg19::chr4:40192656..40192672,+ | p13@RHOH |
Hg19::chr5:133451347..133451358,+ | p3@TCF7 |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
p.value | FDR | nGenes | nPathway | Name |
---|---|---|---|---|
8.30998363188652e-05 | 0.00438351636582014 | 2 | 151 | Wnt signaling pathway (KEGG):04310 |
1.9318817157557e-05 | 0.0017954580611457 | 2 | 73 | Adherens junction (KEGG):04520 |
3.70989802916306e-05 | 0.00234836545246022 | 2 | 101 | Melanogenesis (KEGG):04916 |
0.000389495243957836 | 0.0189654222634854 | 2 | 327 | Pathways in cancer (KEGG):05200 |
1.39045983109694e-05 | 0.00176032214616872 | 2 | 62 | Colorectal cancer (KEGG):05210 |
9.75241122157353e-06 | 0.00176032214616872 | 2 | 52 | Endometrial cancer (KEGG):05213 |
2.8776320508186e-05 | 0.00227692636021022 | 2 | 89 | Prostate cancer (KEGG):05215 |
2.98763831444955e-06 | 0.00176032214616872 | 2 | 29 | Thyroid cancer (KEGG):05216 |
1.09210518403916e-05 | 0.00176032214616872 | 2 | 55 | Basal cell carcinoma (KEGG):05217 |
1.21557119429462e-05 | 0.00176032214616872 | 2 | 58 | Acute myeloid leukemia (KEGG):05221 |
1.98549864581673e-05 | 0.0017954580611457 | 2 | 74 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) (KEGG):05412 |
3.56387285970187e-05 | 0.00234836545246022 | 2 | 99 | Wnt Signaling Pathway and Pluripotency (Wikipathways):WP399 |
4.56530451706939e-05 | 0.00262712523573175 | 2 | 112 | {EP300,115} (Static Module):NA |
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0016055 | Wnt receptor signaling pathway | 0.00732956552454962 |
GO:0021542 | dentate gyrus development | 0.00732956552454962 |
GO:0003702 | RNA polymerase II transcription factor activity | 0.0092791978354083 |
GO:0021766 | hippocampus development | 0.0092791978354083 |
GO:0048341 | paraxial mesoderm formation | 0.0092791978354083 |
GO:0048340 | paraxial mesoderm morphogenesis | 0.0092791978354083 |
GO:0006357 | regulation of transcription from RNA polymerase II promoter | 0.0092791978354083 |
GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB cascade | 0.0092791978354083 |
GO:0048339 | paraxial mesoderm development | 0.0092791978354083 |
GO:0021543 | pallium development | 0.0092791978354083 |
GO:0021761 | limbic system development | 0.0092791978354083 |
GO:0045843 | negative regulation of striated muscle development | 0.0092791978354083 |
GO:0005095 | GTPase inhibitor activity | 0.0092791978354083 |
GO:0008301 | DNA bending activity | 0.0092791978354083 |
GO:0021537 | telencephalon development | 0.0092791978354083 |
GO:0006366 | transcription from RNA polymerase II promoter | 0.0092791978354083 |
GO:0016202 | regulation of striated muscle development | 0.0092791978354083 |
GO:0030879 | mammary gland development | 0.0092791978354083 |
GO:0045449 | regulation of transcription | 0.0092791978354083 |
GO:0019219 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0092791978354083 |
GO:0001890 | placenta development | 0.0092791978354083 |
GO:0001707 | mesoderm formation | 0.0092791978354083 |
GO:0006350 | transcription | 0.0092791978354083 |
GO:0010468 | regulation of gene expression | 0.0092791978354083 |
GO:0048332 | mesoderm morphogenesis | 0.0092791978354083 |
GO:0001704 | formation of primary germ layer | 0.0092791978354083 |
GO:0031323 | regulation of cellular metabolic process | 0.0092791978354083 |
GO:0001756 | somitogenesis | 0.0092791978354083 |
GO:0009966 | regulation of signal transduction | 0.0092791978354083 |
GO:0042475 | odontogenesis of dentine-containing teeth | 0.0092791978354083 |
GO:0019222 | regulation of metabolic process | 0.00975554821880159 |
GO:0042476 | odontogenesis | 0.0109859357310693 |
GO:0007369 | gastrulation | 0.0109859357310693 |
GO:0003705 | RNA polymerase II transcription factor activity, enhancer binding | 0.0109859357310693 |
GO:0035282 | segmentation | 0.0109859357310693 |
GO:0030111 | regulation of Wnt receptor signaling pathway | 0.0109859357310693 |
GO:0017048 | Rho GTPase binding | 0.0121943856283063 |
GO:0030326 | embryonic limb morphogenesis | 0.0121943856283063 |
GO:0035113 | embryonic appendage morphogenesis | 0.0121943856283063 |
GO:0060173 | limb development | 0.0121943856283063 |
GO:0035107 | appendage morphogenesis | 0.0121943856283063 |
GO:0035108 | limb morphogenesis | 0.0121943856283063 |
GO:0048736 | appendage development | 0.0121943856283063 |
GO:0048523 | negative regulation of cellular process | 0.0121943856283063 |
GO:0048513 | organ development | 0.0121943856283063 |
GO:0007165 | signal transduction | 0.0125066031817345 |
GO:0048519 | negative regulation of biological process | 0.0125066031817345 |
GO:0030217 | T cell differentiation | 0.0125066031817345 |
GO:0019210 | kinase inhibitor activity | 0.0125498106132522 |
GO:0007498 | mesoderm development | 0.0128837133747608 |
GO:0030900 | forebrain development | 0.0129505224931683 |
GO:0048732 | gland development | 0.0129505224931683 |
GO:0010467 | gene expression | 0.0129542926297452 |
GO:0007154 | cell communication | 0.0134703643460352 |
GO:0050794 | regulation of cellular process | 0.0141377050911073 |
GO:0009952 | anterior/posterior pattern formation | 0.0141377050911073 |
GO:0002376 | immune system process | 0.0141377050911073 |
GO:0006139 | nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0145933288696284 |
GO:0030098 | lymphocyte differentiation | 0.0158719586635932 |
GO:0050789 | regulation of biological process | 0.0163276894908023 |
GO:0048729 | tissue morphogenesis | 0.0172664430450755 |
GO:0048731 | system development | 0.0173542383735299 |
GO:0017016 | Ras GTPase binding | 0.0178766619077496 |
GO:0031267 | small GTPase binding | 0.0190242123532425 |
GO:0003002 | regionalization | 0.0190242123532425 |
GO:0014706 | striated muscle development | 0.0190242123532425 |
GO:0065007 | biological regulation | 0.0190242123532425 |
GO:0002521 | leukocyte differentiation | 0.0190242123532425 |
GO:0048598 | embryonic morphogenesis | 0.0190242123532425 |
GO:0048869 | cellular developmental process | 0.0190242123532425 |
GO:0030154 | cell differentiation | 0.0190242123532425 |
GO:0009792 | embryonic development ending in birth or egg hatching | 0.0190242123532425 |
GO:0043009 | chordate embryonic development | 0.0190242123532425 |
GO:0051020 | GTPase binding | 0.0190999558344424 |
GO:0042110 | T cell activation | 0.0190999558344424 |
GO:0009968 | negative regulation of signal transduction | 0.0199991029523099 |
GO:0043122 | regulation of I-kappaB kinase/NF-kappaB cascade | 0.0204961650234922 |
GO:0048856 | anatomical structure development | 0.021355071101342 |
GO:0003682 | chromatin binding | 0.0218205910643405 |
GO:0019207 | kinase regulator activity | 0.0222756425717118 |
GO:0007389 | pattern specification process | 0.0223599827367818 |
GO:0000122 | negative regulation of transcription from RNA polymerase II promoter | 0.0226196700769359 |
GO:0007420 | brain development | 0.023874740545571 |
GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 0.023874740545571 |
GO:0007249 | I-kappaB kinase/NF-kappaB cascade | 0.023874740545571 |
GO:0007275 | multicellular organismal development | 0.0253138317106509 |
GO:0048646 | anatomical structure formation | 0.0256646725829836 |
GO:0046649 | lymphocyte activation | 0.0257031865783457 |
GO:0030097 | hemopoiesis | 0.0263935001485549 |
GO:0007166 | cell surface receptor linked signal transduction | 0.0270167344596765 |
GO:0007517 | muscle development | 0.0274262058508522 |
GO:0048534 | hemopoietic or lymphoid organ development | 0.0274262058508522 |
GO:0045321 | leukocyte activation | 0.0282232723868985 |
GO:0002520 | immune system development | 0.0282316155375702 |
GO:0045892 | negative regulation of transcription, DNA-dependent | 0.0311383540634779 |
GO:0001775 | cell activation | 0.0315401295149648 |
GO:0005667 | transcription factor complex | 0.0315401295149648 |
GO:0005515 | protein binding | 0.0315401295149648 |
GO:0045893 | positive regulation of transcription, DNA-dependent | 0.0328047451772009 |
GO:0007417 | central nervous system development | 0.0338734734758142 |
GO:0009790 | embryonic development | 0.0338734734758142 |
GO:0045941 | positive regulation of transcription | 0.0397697947150819 |
GO:0045935 | positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0406682165247854 |
GO:0016481 | negative regulation of transcription | 0.0406682165247854 |
GO:0009888 | tissue development | 0.041688517758191 |
GO:0019899 | enzyme binding | 0.041688517758191 |
GO:0016563 | transcription activator activity | 0.041688517758191 |
GO:0032502 | developmental process | 0.041688517758191 |
GO:0006355 | regulation of transcription, DNA-dependent | 0.041688517758191 |
GO:0045934 | negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0421147710934597 |
GO:0006351 | transcription, DNA-dependent | 0.0425998123255963 |
GO:0032774 | RNA biosynthetic process | 0.0425998123255963 |
GO:0003677 | DNA binding | 0.0436998503780613 |
GO:0009887 | organ morphogenesis | 0.0460300472641261 |
GO:0031325 | positive regulation of cellular metabolic process | 0.0460300472641261 |
GO:0007243 | protein kinase cascade | 0.0469932102717966 |
GO:0031324 | negative regulation of cellular metabolic process | 0.0472041534735815 |
GO:0009893 | positive regulation of metabolic process | 0.0480183820810827 |
GO:0004857 | enzyme inhibitor activity | 0.0485783853784669 |
GO:0032501 | multicellular organismal process | 0.0485783853784669 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>
Ontology term | p-value | n |
---|---|---|
T cell | 2.20e-43 | 25 |
pro-T cell | 2.20e-43 | 25 |
mature alpha-beta T cell | 3.25e-43 | 18 |
alpha-beta T cell | 3.25e-43 | 18 |
immature T cell | 3.25e-43 | 18 |
mature T cell | 3.25e-43 | 18 |
immature alpha-beta T cell | 3.25e-43 | 18 |
lymphoid lineage restricted progenitor cell | 8.84e-30 | 52 |
lymphocyte | 4.28e-29 | 53 |
common lymphoid progenitor | 4.28e-29 | 53 |
CD8-positive, alpha-beta T cell | 3.16e-28 | 11 |
nucleate cell | 8.41e-28 | 55 |
CD4-positive, alpha-beta T cell | 1.86e-19 | 6 |
nongranular leukocyte | 1.65e-14 | 115 |
leukocyte | 2.30e-13 | 136 |
hematopoietic lineage restricted progenitor cell | 2.86e-11 | 120 |
naive T cell | 2.19e-10 | 3 |
hematopoietic stem cell | 2.65e-10 | 168 |
angioblastic mesenchymal cell | 2.65e-10 | 168 |
single nucleate cell | 4.27e-10 | 3 |
mononuclear cell | 4.27e-10 | 3 |
natural killer cell | 8.25e-10 | 3 |
pro-NK cell | 8.25e-10 | 3 |
hematopoietic cell | 2.06e-09 | 177 |
hematopoietic oligopotent progenitor cell | 1.33e-07 | 161 |
hematopoietic multipotent progenitor cell | 1.33e-07 | 161 |
regulatory T cell | 1.56e-07 | 2 |
CD4-positive, CD25-positive, alpha-beta regulatory T cell | 1.56e-07 | 2 |
naive regulatory T cell | 1.56e-07 | 2 |
Ontology term | p-value | n |
---|---|---|
blood | 2.26e-12 | 15 |
haemolymphatic fluid | 2.26e-12 | 15 |
organism substance | 2.26e-12 | 15 |
thymus | 1.82e-08 | 4 |
hemolymphoid system gland | 1.82e-08 | 4 |
thymic region | 1.82e-08 | 4 |
pharyngeal gland | 1.82e-08 | 4 |
thymus primordium | 1.82e-08 | 4 |
hemopoietic organ | 7.13e-08 | 7 |
immune organ | 7.13e-08 | 7 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
MA0003.1 | 0.0137961 |
MA0004.1 | 0.502801 |
MA0006.1 | 0.341337 |
MA0007.1 | 0.483857 |
MA0009.1 | 0.973289 |
MA0014.1 | 0.187674 |
MA0017.1 | 0.991615 |
MA0019.1 | 0.652951 |
MA0024.1 | 0.867125 |
MA0025.1 | 1.10816 |
MA0027.1 | 2.59001 |
MA0028.1 | 0.35747 |
MA0029.1 | 0.886702 |
MA0030.1 | 0.875089 |
MA0031.1 | 0.809638 |
MA0038.1 | 0.60704 |
MA0040.1 | 0.892629 |
MA0041.1 | 0.521615 |
MA0042.1 | 0.48922 |
MA0043.1 | 0.973609 |
MA0046.1 | 0.962263 |
MA0048.1 | 0.382278 |
MA0050.1 | 0.490116 |
MA0051.1 | 0.602745 |
MA0052.1 | 0.896548 |
MA0055.1 | 0.0407081 |
MA0056.1 | 0 |
MA0057.1 | 0.744639 |
MA0058.1 | 0.406232 |
MA0059.1 | 0.404929 |
MA0060.1 | 0.224688 |
MA0061.1 | 0.198335 |
MA0063.1 | 0 |
MA0066.1 | 0.607474 |
MA0067.1 | 1.29359 |
MA0068.1 | 0.946606 |
MA0069.1 | 0.958358 |
MA0070.1 | 0.947018 |
MA0071.1 | 1.39306 |
MA0072.1 | 0.942461 |
MA0073.1 | 0.887754 |
MA0074.1 | 0.60198 |
MA0076.1 | 0.422297 |
MA0077.1 | 0.934645 |
MA0078.1 | 0.703614 |
MA0081.1 | 0.405093 |
MA0083.1 | 0.980893 |
MA0084.1 | 1.48179 |
MA0087.1 | 0.939982 |
MA0088.1 | 0.538456 |
MA0089.1 | 0 |
MA0090.1 | 0.436918 |
MA0091.1 | 0.505453 |
MA0092.1 | 0.467172 |
MA0093.1 | 0.344385 |
MA0095.1 | 0 |
MA0098.1 | 0 |
MA0100.1 | 0.621149 |
MA0101.1 | 0.347695 |
MA0103.1 | 0.332048 |
MA0105.1 | 0.340955 |
MA0106.1 | 0.648997 |
MA0107.1 | 0.274127 |
MA0108.2 | 0.806528 |
MA0109.1 | 0 |
MA0111.1 | 1.14351 |
MA0113.1 | 0.665691 |
MA0114.1 | 0.741402 |
MA0115.1 | 1.21667 |
MA0116.1 | 0.760835 |
MA0117.1 | 1.01134 |
MA0119.1 | 0.388712 |
MA0122.1 | 1.03753 |
MA0124.1 | 1.17486 |
MA0125.1 | 1.0901 |
MA0130.1 | 0 |
MA0131.1 | 0.722072 |
MA0132.1 | 0 |
MA0133.1 | 0 |
MA0135.1 | 1.00402 |
MA0136.1 | 1.491 |
MA0139.1 | 0.186511 |
MA0140.1 | 0.564957 |
MA0141.1 | 1.04059 |
MA0142.1 | 0.777365 |
MA0143.1 | 0.66587 |
MA0144.1 | 0.708913 |
MA0145.1 | 0.276317 |
MA0146.1 | 0.0610556 |
MA0147.1 | 0.281049 |
MA0148.1 | 0.528066 |
MA0149.1 | 0.555119 |
MA0062.2 | 1.07166 |
MA0035.2 | 0.564239 |
MA0039.2 | 0.0553061 |
MA0138.2 | 0.704862 |
MA0002.2 | 0.611548 |
MA0137.2 | 0.95459 |
MA0104.2 | 0.223944 |
MA0047.2 | 0.636643 |
MA0112.2 | 0.0758925 |
MA0065.2 | 0.282161 |
MA0150.1 | 0.430951 |
MA0151.1 | 0 |
MA0152.1 | 0.571637 |
MA0153.1 | 1.07307 |
MA0154.1 | 0.335384 |
MA0155.1 | 0.534073 |
MA0156.1 | 1.7082 |
MA0157.1 | 0.749547 |
MA0158.1 | 0 |
MA0159.1 | 0.281681 |
MA0160.1 | 0.543522 |
MA0161.1 | 0 |
MA0162.1 | 0.25944 |
MA0163.1 | 0.942271 |
MA0164.1 | 0.678332 |
MA0080.2 | 0.911393 |
MA0018.2 | 0.650405 |
MA0099.2 | 0.572 |
MA0079.2 | 0.263996 |
MA0102.2 | 1.51913 |
MA0258.1 | 0.245543 |
MA0259.1 | 0.289405 |
MA0442.1 | 0 |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
No analysis results for this cluster
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.